# Phase I Study of Mesenchymal Stromal Cell Secretome for Promoting Corneal Regeneration

> **NIH NIH UH3** · UNIVERSITY OF ILLINOIS AT CHICAGO · 2024 · $332,234

## Abstract

Summary
The Mesenchymal Stromal Cell (MSC) Secretome Study is designed to assess the safety of allogeneic
bone marrow-derived MSC secreted factors on the ocular surface, and also obtain a preliminary
observation on 1) epithelial healing; 2) development of scarring; and 3) final visual acuity; with the
objective of improving clinical outcomes in significant non-healing corneal epithelial disease. To achieve
these goals, the MSC Secretome Study will include a Phase 1 safety and maximum tolerated dose study
(Specific Aim #1) and a Phase 2a double- masked vehicle-controlled study to assess preliminary evidence
of efficacy while identifying patient subgroups most likely to benefit from the treatment (Specific Aim#2).

## Key facts

- **NIH application ID:** 11145412
- **Project number:** 3UH3EY031809-04S1
- **Recipient organization:** UNIVERSITY OF ILLINOIS AT CHICAGO
- **Principal Investigator:** ALI R DJALILIAN
- **Activity code:** UH3 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $332,234
- **Award type:** 3
- **Project period:** 2020-09-30 → 2025-09-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11145412

## Citation

> US National Institutes of Health, RePORTER application 11145412, Phase I Study of Mesenchymal Stromal Cell Secretome for Promoting Corneal Regeneration (3UH3EY031809-04S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/11145412. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*